TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05747937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A punch skin biopsy of 3mm will be used to analyze cutaneous innervation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: A punch skin biopsy of 3mm will be used to analyze cutaneous innervation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: SCOPA-AUT autonomic symptoms scale; Brief Pain Inventory questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dinamic Sweat Test
Description: Test for the functional assessment of postganglionic sudomotor pathway

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dinamic Sweat Test
Description: Test for the functional assessment of postganglionic sudomotor pathway
Study: NCT06276543

Intervention type: DEVICE
Intervention: antibiotic-impregnated catheter
Description: Hydrocephalus patient implant with antibiotic-impregnated catheter to shunt their cerebrospinal fluid.
Study: NCT06077591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Derived Tumor Organoids
Description: Intervention in this study is to perform tissue sampling to patient's tumor which are then subjected to DNA extraction for whole exome sequencing, organoid culture, and drug screen. An MDT board will review the drug screen results and excluded drug choice of poor response. Then the referring oncologist has the final discretion on the choice of chemo- or targeted agent as usual.
Study: NCT05767970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Stress Toolbox for Healthcare Providers (ISTH)
Description: The ISTH is a 12-week meditation-based well-being training. In weeks 1-8, participants engage in weekly 2-hour class sessions that are recorded and posted on a private Youtube channel for one week. There is a final two-hour session at week 12. In-class learning is augmented and extended through content in a special version of the Healthy Minds Program smartphone app that participants are asked to use on a daily basis throughout the intervention.
Study: NCT06230224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered by IV infusion, as part of the ICE ± R salvage therapy
Study: NCT06090539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986458
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986458
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986458
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days.
Study: NCT06482229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application for postoperative analgesia
Description: three different methods will be applied to reduce patients' postoperative pain
Study: NCT06230224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Administered by IV infusion, as part of the DHAP ± R salvage therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered by IV infusion, as part of the GDP ± R salvage therapy.
Study: NCT06534983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autogene Cevumeran
Description: Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
Study: NCT06778694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Description: Bridging Dead bug Plank Pelvic tilts Squatting and lunges

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated strengthening lumbar exercises
Description: Child pose Mckenzie Lat pull down Russian twist
Study: NCT06534983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline solution for intravenous infusion
Study: NCT06548542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-382
Description: Subcutaneous Injection
Study: NCT04722315

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Description: 12 weeks of modified Atkins diet
Study: NCT04750252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StroMel
Description: Autologous MSC
Study: NCT04524000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study: NCT05673785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablets
Study: NCT04681638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pathogen-Reduced Plasma
Description: The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL\*kg\*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL\*kg\*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.
Study: NCT04927637

Intervention type: PROCEDURE
Intervention: imaging 24 hours following intravenous administration of ICG
Description: Patients will be administered a single, FDA approved, ICG, 2.5-5mg/kg dose 24 hours prior to surgery. ICG fluorescence images will be acquired By a FDA approved surgical imaging device prior to surgical debridement. The wound will be irrigated as per standard procedure and another ICG fluorescence image will be acquired. The need for repeat debridement or tissue cultures will be left up to the treating surgeon.
Study: NCT05273164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training
Description: Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Participants will complete computerized cognitive training developed by Posit Science Corporation. For a description of the training paradigms please review arm descriptions.
Study: NCT06564285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG1 - Nutritional Supplement
Description: A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT06495567

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: For 7 days, participants will take a 20mg creatine supplement each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary methionine tracer and protein intake
Description: On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary methionine tracer and protein intake
Description: On the study days participants will ingest 8 hourly meals of controlled amino acid intake, fortified with the necessary macronutrients. Each meal will provide one-twelfth of the participants' daily energy requirements as estimated by 1.5 x Resting Energy Expenditure (REE) and adequate protein at 1.0 g/kg/d, to maintain a metabolic steady state. The meals are in the form of a crystalline amino acid protein shake, and protein-free cookies.
Study: NCT05687539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastiha water
Description: 10ml of mastiha water before every meal for one month

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mastiha capsules
Description: 2x350mg mastiha capsules before every meal for one month
Study: NCT06565156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BR-AM
Description: BR-AM is a single-layer amniotic membrane allograft. BR-AM is manufactured by BioStem Technologies, Inc. and is processed by the bioREtain method which, briefly, includes initial disinfection, processing with isotonic solutions, dehydration at 37-40°C and electron beam sterilization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard of care is defined as:~* Debridement,~* Wound cleansing with a neutral, non-irritating and non-toxic solution,~* Non-adherent wound contact layer, a foam pad, alginate or hydrofiber dressing for moderately draining wounds, a secondary retention bandage, and~* An off-loading device.
Study: NCT06045078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil Lavender-peppermint Aromatabs
Description: 100% pure essential oils Lavender-peppermint aromatabs purchased through Beekley Medical

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Elequil Almond-Oil Aromatabs
Description: 100% pure essential oils Almond-oil aromatabs purchased through Beekley Medical
Study: NCT05321420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: pirfenidone 801 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deupirfenidone
Description: Deupirfenidone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deupirfenidone
Description: Deupirfenidone
Study: NCT06312813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 4% imipramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: 4% amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: 0.1ml propylene glycol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: 0.1ml propylene glycol
Study: NCT06482229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application for postoperative analgesia
Description: three different methods will be applied to reduce patients' postoperative pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: application for postoperative analgesia
Description: three different methods will be applied to reduce patients' postoperative pain
Study: NCT05834400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Optimal Lymph FLow (TOLF)
Description: Participants in TOLF intervention will complete initial in-person 40-minute session on TOLF lymphatic exercise training and daily monitoring, and 3 virtual 15-minute telehealth sessions to enhance their skills over the course of 4 weeks. These sessions will be conducted by the TOLF interventionist of the study. For 4-week study duration, participants will be asked to practice the set of 8 lymphatic exercises twice a day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Monitoring
Description: Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
Study: NCT05145413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID
Study: NCT05834400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Monitoring
Description: Participants will complete initial in-person training on daily monitoring of weight, heart rate and blood pressure, fluid overload symptoms; and 3 conferencing coaching sessions conducted by the monitoring coach to enhance their skills. Over the course of 4 weeks, Participants will monitor these daily fluid overload parameters and symptoms
Study: NCT06510777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO Treatment
Description: PICO 7 is a single-use Negative Pressure Wound Therapy System consisting of a small portable pump, 2 AA batteries, 1 or 2 dressings, and fixation strips. The dressing is changed when the dressing is saturated or after 7 days of treatment.~PICO Treatment will be given in addition to compression therapy.~If the wound is healed and until the wound healing confirmation visit, Venous Leg Ulcers (VLUs) allocated to the PICO group may be covered using a protective dressing.~If the wound meets the wound improvement criteria as assessed by the PI during the monthly visits, PICO treatment may be stopped.
Study: NCT05145413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study: NCT06035120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal System
Description: The AeriSeal System comprises AeriSeal Foam and the AeriSeal Balloon Catheter Preparation Kit that is used for bronchoscopic delivery of AeriSeal Foam to the targeted regions of the lung.
Study: NCT06510777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) Treatment
Description: Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC) Treatment
Description: Application of an appropriate wound primary dressing according to its intended purpose and chosen appropriately according to wound healing stage:~1. Dressing choice should take wound condition into consideration but may also consider subject's comfort (including pain) and HCP's preference.~2. Sequential treatment:~   * Debridement stage: alginate, hydrogel, absorbent, or hydro-detersive dressings~  * Granulation stage: wound contact layer, foam, petrolatum, or hydrofiber dressings~  * Epithelialization stage: wound contact layer, hydrocolloids~  * Other: dressings for specific clinical situations (e.g. fragile skin, infection; hemorrhagic wound, malodorous wound)~3. Application of appropriate venous compression therapy based on Ankle Brachial Pressure Index (ABPI) value.